

11th November 2022

Imbruvica (ibrutinib): New risk minimisation measures, including dose modification recommendations, due to the increased risk for serious cardiac events

Dear Healthcare professional,

Janssen-Cilag Limited, UK in agreement with the European Medicines Agency (EMA) and Medicines and Healthcare products Regulatory Agency (MHRA) would like to inform you of the following:

Summary

- **Ibrutinib increases the risk of fatal and serious cardiac arrhythmias and cardiac failure.**
- **Patients with advanced age, Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2 , or cardiac co-morbidities may be at greater risk of cardiac events including sudden fatal cardiac events.**
- **Prior to initiating ibrutinib, clinical evaluation of cardiac history and function should be performed.**
- **In patients with risk factors for cardiac events, benefits and risks should be assessed before initiating treatment with Imbruvica; alternative treatment may be considered.**
- **Patients should be carefully monitored during treatment for signs of deterioration of cardiac function and if this occurs, clinically managed.**
- **Ibrutinib should be withheld for any new onset or worsening grade 2 cardiac failure or grade 3 cardiac arrhythmias. Treatment may be resumed as per new dose modification recommendations (details below).**

Background on the safety concern

Ibrutinib is authorised for some types of mantle cell lymphoma (MCL), chronic lymphocytic leukaemia (CLL), and Waldenström's macroglobulinaemia (WM) – consult the Summary of Product Characteristics (SmPC) for full indication <https://www.medicines.org.uk/emc/>.

Assessment of data from the randomised clinical trials (RCT) pool of ibrutinib showed a nearly 5-fold higher crude incidence of sudden cardiac death, sudden death, or cardiac death in the ibrutinib arm (11 cases; 0.48%) versus the comparator arm (2 cases; 0.10%). When adjusted for exposure, a 2-fold increase in the incidence rate (EAIR, expressed as number of subjects with events divided by patient-months at risk) of events of sudden cardiac death, sudden death or cardiac death was observed in the ibrutinib arm (0.0002) versus the comparator arm (0.0001).

Based on an assessment of available data on the cardiotoxicity of ibrutinib, further measures to minimize the cardiac risk have been implemented in the product information. Patients with advanced age, Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2 , or cardiac co-morbidities may be at greater risk of events including sudden fatal cardiac events.

Appropriate clinical evaluation of cardiac history and function should be performed prior to initiating Imbruvica. Patients should be carefully monitored during treatment for signs of clinical deterioration of cardiac function and if this occurs, clinically managed. Consider further evaluation (e.g., ECG, echocardiogram), as indicated for patients in whom there are cardiovascular concerns.

For patients with relevant risk factors for cardiac events, carefully assess benefit/risk before initiating treatment with Imbruvica; alternative treatments may be considered.

Section 4.4 of the SmPC has is being updated accordingly and cardiac arrest is being added as an ADR in Section 4.8 of the SmPC – see <https://www.medicines.org.uk/emc/>.

In addition, the MAH reviewed clinical data for patients experiencing Grade 3+ cardiac events and assessed whether toxicities recurred for patients who dose-reduced IMBRUVICA versus patients who did not dose reduce subsequent to these toxicities. Analyses indicate a lower incidence of recurrence of cardiac events for patients who dose-reduced IMBRUVICA compared to those who did not reduce the dose of IMBRUVICA.

On this basis, section 4.2 of the EU SmPC is being updated with new recommendations as follows:

Imbruvica therapy should be withheld for any new onset or worsening grade 2 cardiac failure or grade 3 cardiac arrhythmias. Once the symptoms of the toxicity have resolved to grade 1 or baseline (recovery), resume Imbruvica therapy at the recommended dose as per the table below:

Events	Toxicity occurrence	MCL dose modification after recovery	CLL/WM dose modification after recovery
Grade 2 cardiac failure	First	Restart at 420 mg daily	Restart at 280 mg daily
	Second	Restart at 280 mg daily	Restart at 140 mg daily
	Third	discontinue Imbruvica	
Grade 3 cardiac arrhythmias	First	Restart at 420 mg daily [†]	Restart at 280 mg daily [†]
	Second	discontinue Imbruvica	
Grade 3 or 4 cardiac failure Grade 4 cardiac arrhythmias	First	discontinue Imbruvica	

[†] Evaluate the benefit-risk before resuming treatment.

Recommended dose modifications for non-cardiac events (grade ≥ 3 non-haematological toxicity, grade ≥ 3 neutropenia with infection or fever, or grade 4 haematological toxicities) remain mainly unchanged with the addition of the following footnote in the table: "When resuming treatment, restart at the same or lower dose based on benefit-risk evaluation. If the toxicity reoccurs, reduce daily dose by 140 mg".

Call for reporting

Healthcare professionals should report any suspected adverse reactions associated with the use of Imbruvica in accordance with the national spontaneous reporting system.

Please continue to report suspected adverse reactions with any medicine or vaccine to the MHRA through the Yellow Card Scheme.

It is easiest and quickest to report adverse drug reactions online via the Yellow Card website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Alternatively, you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours.

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset dates, treatment dates, product brand name and batch numbers.

Suspected adverse reactions should also be reported to Janssen-Cilag Limited. on tel.: 01494 567447, or by e-mail at dsafety@its.jnj.com.

Company contact point

If you have further questions or require additional information, please contact: Janssen Medical Information Department: email: medinfo@its.jnj.com, telephone: 0800 731 8450 or 01494 567 444.

Sincerely,
Janssen-Cilag Ltd



Paresh Sewpaul
Therapy Area Medical Director - Haematology